Pharmacokinetic Consideration of Venetoclax in Acute Myeloid Leukemia Patients: A Potential Candidate for TDM? A Short Communication - Archive ouverte HAL Access content directly
Journal Articles Therapeutic Drug Monitoring Year : 2024

Pharmacokinetic Consideration of Venetoclax in Acute Myeloid Leukemia Patients: A Potential Candidate for TDM? A Short Communication

Abstract

Background: Venetoclax (VNX)-based regimens have demonstrated significantly favorable outcomes in patients with acute myeloid leukemia (AML) and are now becoming the standard treatment. Tyrosine kinase inhibitors are administered at a fixed dose, irrespective of body surface area or weight. For such orally targeted therapies, real-world data have highlighted a larger pharmacokinetic (PK) interindividual variability (IIV) than expected. Even if VNX PKs have been well characterized and described in the literature, only 1 clinical trial–based PK study has been conducted in patients with AML. This study aimed to evaluate the PK of VNX in AML patients. Material and methods: We retrospectively analyzed all patients treated with a combination of VNX–azacitidine between January and July 2022 at our center, using at least 1 available VNX blood sample. Based on a previously published population PK model, individual PK parameters were estimated to evaluate the exposure and IIV. Results: and Discussion. Twenty patients received VNX in combination with azacitidine, according to the PK data. A total of 93 plasma concentrations were collected. The dose of VNX was 400 mg, except in 7 patients who received concomitant posaconazole (VNX 70 mg). The patients' weight ranged from 49 kg to 108 kg (mean = 78 kg). Mean individual clearance was 13.5 ± 9.4 L/h with mean individual daily area under the concentration–time curves of 35.8 mg.h/L with significant IIV (coefficient of variation = 41.1%). Ten patients were still alive (8 in complete response), but all experienced at least 1 hematological toxicity of grade ≥ 3. Conclusions: Based on the observed large PK variability in the data from our real-world AML patients, the risk of drug interactions and the recommended fixed-dosage regimen of VNX therapeutic drug monitoring may be useful.

Domains

Pharmacology
No file

Dates and versions

hal-04622600 , version 1 (24-06-2024)

Identifiers

Cite

Michael Philippe, Jérôme Guitton, Sylvain Goutelle, Yann Thoma, Bertrand Favier, et al.. Pharmacokinetic Consideration of Venetoclax in Acute Myeloid Leukemia Patients: A Potential Candidate for TDM? A Short Communication. Therapeutic Drug Monitoring, 2024, 46 (1), pp.127-131. ⟨10.1097/FTD.0000000000001151⟩. ⟨hal-04622600⟩
0 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More